![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A ALTUVIIIO provides high-sustained factor...
Communiqué de presse : Le NEJM publie les données de phase III de l’étude XTEND-Kids montrant qu’ALTUVIIIO a le potentiel de transformer la prise en charge thérapeutique des enfants atteints...
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD...
Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenne Dupixent devient le tout premier médicament ciblé pour...
Communiqué de presse : Publication dans le NEJM des données positives de phase III du Dupixent dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 12 mois à 11 ans...
Press Release: Availability of the Q2 2024 Aide-mémoire Availability of the Q2 2024 Aide-mémoire Paris, France – June 25, 2024. Sanofi announced that its Q2 2024 Aide-mémoire is available on...
Communiqué de presse : Audrey Duval Derveloy nommée Directrice Affaires Corporate Groupe, membre du Comité exécutif de Sanofi Audrey Duval Derveloy nommée Directrice Affaires Corporate...
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.03 | 0.0319454797146 | 93.91 | 94.33 | 90.73 | 1202632 | 92.19915345 | DE |
4 | 5.9 | 6.70149931849 | 88.04 | 94.91 | 87.53 | 1434621 | 91.57856397 | DE |
12 | 2.28 | 2.48745363299 | 91.66 | 94.91 | 85.94 | 1484394 | 90.51694693 | DE |
26 | 0.23 | 0.24543805357 | 93.71 | 94.91 | 84.93 | 1442800 | 89.52601039 | DE |
52 | -4.99 | -5.04397048418 | 98.93 | 104.32 | 80.6 | 1460959 | 91.38323891 | DE |
156 | 6.94 | 7.97701149425 | 87 | 106.66 | 76.45 | 1781341 | 91.37036362 | DE |
260 | 18.94 | 25.2533333333 | 75 | 106.66 | 67.65 | 2010018 | 88.07411886 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions